Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | EXECUTIVE VICE PRESIDENT | May 10, 2024 | May 14, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date May 10, 2024 · Filed May 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 211,341 |
Ending reported balance
After 2024-05-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-05-10 · Exercise / conversion · Acquired 10,097 · Balance 221,438 Row 2 · 2024-05-10 · Sale · Disposed 10,097 · Balance 211,341 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.55 to $104.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.00 · Expires 2025-02-19 | Direct | 45,000 |
Reported balance
After 2024-05-10 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-05-10 · Exercise / conversion · Disposed 10,097 · Balance 45,000 F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Trust | 20,000 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 20,000 F2: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Trust | 20,000 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 20,000 F2: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 18,765 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 18,765 F3: Balance in the Abbott Laboratories Stock Retirement Trust as of May 10, 2024. |
| Common shares without par valueSEC Table I · non-derivative | IndirectBy Daughter | 500 |
Reported balance
Holding disclosure · report date 2024-05-10 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 500 F4: The reporting person disclaims beneficial ownership of all securities held by his daughter. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.55 to $104.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust.
F3: Balance in the Abbott Laboratories Stock Retirement Trust as of May 10, 2024.
F4: The reporting person disclaims beneficial ownership of all securities held by his daughter.
F5: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2024 Filed May 14, 2024 21:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 10,097 | $0.00 Strike: $47.00 | $0.00 |
DisclosureSEC source: 0001415889-24-013146 · form4-05142024_090502.xml · derivative · entry 7 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 10,097 shares Expires 2025-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| May 10, 2024 Filed May 14, 2024 21:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 10,097 | $104.57 | $1,055,819.06 |
DisclosureSEC source: 0001415889-24-013146 · form4-05142024_090502.xml · nonDerivative · entry 2 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,341 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $104.55 to $104.62, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 10, 2024 Filed May 14, 2024 21:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 10,097 | $47.00 | $474,559.00 |
DisclosureSEC source: 0001415889-24-013146 · form4-05142024_090502.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 00:00 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,415 | $120.05 | $1,370,370.75 |
DisclosureSEC source: 0001415889-24-006408 · form4-03052024_120326.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,341 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 92,137 | $0.00 Strike: $116.98 | $0.00 |
DisclosureSEC source: 0001415889-24-005092 · form4-02232024_100245.xml · derivative · entry 6 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,137 Underlying: Common Shares · 92,137 shares Expires 2034-02-20 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,712 on February 21, 2025, 30,712 on February 21, 2026, and 30,713 on February 21, 2027. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:29 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,519 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005092 · form4-02232024_100245.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,756 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 21:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013307 · form4-09152023_090915.xml · nonDerivative · entry 3 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 20,000 F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 21:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013307 · form4-09152023_090915.xml · nonDerivative · entry 2 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 20,000 F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. Read SEC document |
| September 13, 2023 Filed Sep 15, 2023 21:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-013307 · form4-09152023_090915.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,237 Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 00:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,264 | $100.70 | $127,284.80 |
DisclosureSEC source: 0001415889-23-003907 · form4-03032023_120303.xml · nonDerivative · entry 2 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,237 Read SEC document |
| February 28, 2023 Filed Mar 3, 2023 00:35 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 11,500 | $99.77 | $1,147,355.00 |
DisclosureSEC source: 0001415889-23-003907 · form4-03032023_120303.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 219,501 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 96,301 | $0.00 Strike: $106.24 | $0.00 |
DisclosureSEC source: 0001415889-23-003052 · form4-02222023_110236.xml · derivative · entry 6 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,301 Underlying: Common Shares · 96,301 shares Expires 2033-02-16 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 32,100 on February 17, 2024, 32,100 on February 17, 2025, and 32,101 on February 17, 2026. Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 23:53 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-003052 · form4-02222023_110236.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,001 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 28, 2022 Filed Mar 3, 2022 00:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,750 | $122.41 | $1,315,907.50 |
DisclosureSEC source: 0001415889-22-002192 · form4-03022022_040325.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,582 Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 133,670 | $0.00 Strike: $117.58 | $0.00 |
DisclosureSEC source: 0001415889-22-001736 · form4-02232022_050248.xml · derivative · entry 6 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,670 Underlying: Common Shares · 133,670 shares Expires 2032-02-17 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 44,556 on February 18, 2023, 44,557 on February 18, 2024, and 44,557 on February 18, 2025. Read SEC document |
| February 18, 2022 Filed Feb 24, 2022 01:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 28,682 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001736 · form4-02232022_050248.xml · nonDerivative · entry 1 Funck, Jr. Robert E. · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,332 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 21:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-002225 · form4-04302021_020445.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,650 Read SEC document |
| February 26, 2021 Filed Mar 3, 2021 00:23 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 10,136 | $121.58 | $1,232,334.88 |
DisclosureSEC source: 0001415889-21-001205 · form4-03022021_040341.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,350 Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 123,966 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000892 · form4-02232021_030200.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 123,966 Underlying: Common Shares · 123,966 shares Expires 2031-02-18 F5 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 41,322 on February 19, 2022, 41,322 on February 19, 2023, and 41,322 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 23:51 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 24,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000892 · form4-02232021_030200.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,486 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 31,325 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001415889-21-000535 · form4-02042021_030210.xml · derivative · entry 7 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 31,325 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 18,241 | $122.54 | $2,235,252.14 |
DisclosureSEC source: 0001415889-21-000535 · form4-02042021_030210.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,301 Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 23:56 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 31,325 | $39.12 | $1,225,434.00 |
DisclosureSEC source: 0001415889-21-000535 · form4-02042021_030210.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002992 · form4-12182020_041255.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,000 F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002992 · form4-12182020_041255.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,000 F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GiftCommon shares without par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002992 · form4-12182020_041255.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,217 Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 83,333 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-010699 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 83,333 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 83,333 | $108.83 | $9,068,955.39 |
DisclosureSEC source: 0001179110-20-010699 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,217 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.75 to $108.93, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 22:33 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 83,333 | $38.40 | $3,199,987.20 |
DisclosureSEC source: 0001179110-20-010699 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 13,000 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · derivative · entry 8 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,325 Underlying: Common shares · 13,000 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 23,700 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · derivative · entry 7 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 23,700 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 23,855 | $98.00 | $2,337,790.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,217 Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 13,000 | $39.12 | $508,560.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2020 Filed Apr 24, 2020 01:27 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 23,700 | $34.94 | $828,078.00 |
DisclosureSEC source: 0001179110-20-005068 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,072 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,356 | $77.89 | $105,618.84 |
DisclosureSEC source: 0001179110-20-002920 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,372 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:28 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 6,710 | $79.19 | $531,364.90 |
DisclosureSEC source: 0001179110-20-002920 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,728 Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 154,013 | $0.00 Strike: $87.72 | $0.00 |
DisclosureSEC source: 0001179110-20-002264 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154,013 Underlying: Common shares · 154,013 shares Expires 2030-02-20 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 51,337 on February 21, 2021, 51,338 on February 21, 2022, and 51,338 on February 21, 2023. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 22:14 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 25,265 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-20-002264 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,438 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $34.94 | $0.00 |
DisclosureSEC source: 0001179110-19-009489 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,700 Underlying: Common shares · 40,000 shares Expires 2023-02-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 26,818 | $85.56 | $2,294,548.08 |
DisclosureSEC source: 0001179110-19-009489 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,173 Read SEC document |
| August 09, 2019 Filed Aug 13, 2019 23:11 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 40,000 | $34.94 | $1,397,600.00 |
DisclosureSEC source: 0001179110-19-009489 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,991 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 1,002 | $78.00 | $78,156.00 |
DisclosureSEC source: 0001179110-19-003116 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,991 Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 22:24 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 4,680 | $77.23 | $361,436.40 |
DisclosureSEC source: 0001179110-19-003116 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,993 Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 122,367 | $0.00 Strike: $75.90 | $0.00 |
DisclosureSEC source: 0001179110-19-002641 · edgar.xml · derivative · entry 5 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,367 Underlying: Common shares · 122,367 shares Expires 2029-02-21 F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 40,789 on February 22, 2020, 40,789 on February 22, 2021, and 40,789 on February 22, 2022. Read SEC document |
| February 22, 2019 Filed Feb 26, 2019 22:08 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 23,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-19-002641 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,673 F1 · shares: These shares represent performance-based restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 14,400 | $0.00 Strike: $27.03 | $0.00 |
DisclosureSEC source: 0001179110-18-011220 · edgar.xml · derivative · entry 10 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 14,400 shares Expires 2022-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 12,300 | $0.00 Strike: $22.39 | $0.00 |
DisclosureSEC source: 0001179110-18-011220 · edgar.xml · derivative · entry 9 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 12,300 shares Expires 2021-02-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionOption (right to buy) · Derivative | 9,700 | $0.00 Strike: $26.19 | $0.00 |
DisclosureSEC source: 0001179110-18-011220 · edgar.xml · derivative · entry 8 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 9,700 shares Expires 2020-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 23,751 | $67.11 | $1,593,929.61 |
DisclosureSEC source: 0001179110-18-011220 · edgar.xml · nonDerivative · entry 4 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,329 Read SEC document |
| September 05, 2018 Filed Sep 7, 2018 21:15 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Exercise / conversionCommon shares without par value | 14,400 | $27.03 | $389,283.84 |
DisclosureSEC source: 0001179110-18-011220 · edgar.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.